A Patient-Reported Outcomes Analysis Of Lanreotide In The Treatment Of NETs Patients With Carcinoid Syndrome

11th November 2019
The purpose of this analysis of patient-reported outcomes from the ELECT (Evaluation of Lanreotide Depot/Autogel Efficacy and Safety as a Carcinoid Syndrome Treatment) trial (NCT00774930) was to...
Learn More

Valuing Pharmaceutical Assets: When to Use NPV vs rNPV

15th October 2019
Preview: A variety of approaches have been developed to evaluate pharmaceutical assets, but two similar yet distinct methods are most commonly used. Venture capitalists and large investment firms...
Learn More

Adeno-Associated Virus Gene Therapy Landscape

24th September 2019
Adeno-associated viruses (AAV) are virus particles composed of single-stranded DNA surrounded by a protein shell. Despite their simple structure, recombinant AAVs (rAAV) can perform the important...
Learn More

Pharma & Biotech Due Diligence Insight

01st September 2019
For close to fifteen years, Alacrita has been an expert resource for due diligence and valuation services covering pharmaceuticals and biotechnology. This paper shares some of the insights we've...
Learn More

Pharmaceutical Due Diligence Checklist | Biotech Due Diligence Best Practices

23rd August 2019
For close to fifteen years, Alacrita has been an expert resource for due diligence and valuation services covering pharmaceuticals and biotechnology. This paper shares some of the insights we've...
Learn More

FDA Expedited Programs for Cancer Drug Development: Don’t Believe the Doubters

16th August 2019
Intro:
Learn More

Pharmaceutical Patent Term Extension: An Overview

27th March 2019
Pharmaceutical Patent Term Extension: An Overview About the authors: Scott Whittaker is an Alacrita Associate and Robert Johnson is Managing Partner of the firm’s Boston office. Anthony Walker is a...
Learn More

Pharmaceutical Probability of Success

19th October 2018
Abstract: Critical strategic decisions are made based on valuation models of pharmaceutical assets. Of the many assumptions that underpin a valuation model, probability of success is a key input, but...
Learn More

Leveraging Diagnostics to Realize the Full Potential of Precision Oncology

07th July 2017
As we approach the twentieth anniversary of the approval of Herceptin, the field of precision oncology has never been more exciting or dynamic, and utility seems to be broadly recognized. Precision...
Learn More

Commercialization of Cellular Immunotherapies

07th May 2016
Commercialization of Cellular Therapies Biochemical Society Transactions Apr 11, 2016,44(2)329-332; DOI: 10.1042/BST20150240 Abstract Successful commercialization of a cell therapy requires more than...
Learn More

What's wrong with NPV valuations?

26th October 2015
Risk-adjusted NPV is Notoriously Fallible Over at least the past decade, risk-adjusted Net Present Value (rNPV) has emerged as the de facto standard for valuing pharmaceutical R&D projects (1,2)....
Learn More

Medtech: how to succeed in Europe

20th March 2014
Amidst a currently effervescent biotech scene, medtech is suffering. Sector newsflow is dominated by layoffs, regulatory escalation and a harsh fiscal environment. In this context, it is appealing...
Learn More
Previous
1 2 3 4
Next

Need biotech consulting support? We can help.

Contact us today to learn how our pharma & biotech consulting expertise can serve your project.

Contact us

Explore our biotech & life science consulting services

© 2009-24 Alacrita Holdings Limited  |   Pharma & Biotech Consulting

Alacrita Consulting 
2 Royal College St
London, UK
NW1 0NH

Registered in England & Wales.
No. 10530608


One Broadway
Floor 14
Cambridge, MA 02142

Registered in Massachusetts.